

Ref: NLL\CS\2011-88\

Dated: 11.03.2010

BY FAX / COURIER

1. National Stock Exchange of India Limited
'G' Block, Exchange Plaza, Bandra Kurla Complex,
Bandra (East), MUMBAI – 400 051.
2. Bombay Stock Exchange Limited
Phiroze Jeejeebhoy Towers, Dalal Street,
MUMBAI – 400 001.

Sub. Investors Information Release

Dear Sirs,

Please find attached herewith an Investor Information release that "NecLife announces the receipt of Japanese MOH approval for Cefuroxime Axetil".

This is for your information and record please.

Thanking you,

Yours faithfully,

For ~~Nectar~~ Lifesciences Limited


Sunder Lal
Company Secretary



NECTAR LIFESCIENCES LIMITED

Soo 38-39, Sector 9-D, Madhya Marg, Chandigarh 160009, U.T., India

For immediate release

NecLife announces the receipt of Japanese MOH approval for Cefuroxime Axetil

Chandigarh, March 11, 2011

Nectar Lifesciences Limited (NecLife), a leading integrated pharmaceutical organization in India, today announced that it has received approval from the Japanese MOH for their key product i.e. Cefuroxime Axetil.

Business Opportunities in Japan

The Japanese approval marks a significant achievement for the Company and demonstrates further progress made towards entering highly regulated and stringent markets like Japan. Japan with a GDP of USD 5.39 trillion (2010) is well poised to register steady growth in the pharma market in the near future on account of its expanding generic market. Currently, the market size of Pharma in Japan is ~ USD 68 billion and is expected to increase to ~ USD 82 billion in the next few years on account of increasing incentives by the Government for promoting generics like providing incentives for prescribing generics & increasing patient awareness. NecLife expects business potential for the approved molecule "Cefuroxime Axetil" to be ~ USD 10 million.

Commenting on this development, Mr. Dinesh Dua, CEO & Director of Nectar Lifesciences Limited said:

"Getting approval for Cefuroxime Axetil is yet another important milestone & achievement. The Japanese audit is one of the most stringent globally & the fact that we have been approved by Japanese MOH marks our journey in the regulated path. This approval enables us to further augment our position in the cephalosporin market in three major oral molecules: Cefuroxime Axetil, Cefixime Trihydrate & Cefpodoxime Proxetil along with key sterile molecules like Ceftriaxone Sodium & Cefotaxime Sodium.

We remain excited about the current scenario of the pharma markets around the globe and are making stable progress towards securing approvals in other key markets"

Certified to be true copy
For Nectar Lifesciences Limited

Sunder Lal
Company Secretary

About Nectar Lifesciences Limited (NecLife)

Established in 1995, NecLife (BSE code: 532649, NSE Id: NECLIFE, ISIN Id: INE023H01027) is a leading integrated pharmaceutical organization in India, offering a specialized comprehensive range of oral and sterile cephalosporin and Carbapenem active pharmaceutical ingredients (APIs) and finished dosage forms (FDFs). The Company is growing presence in empty hard gelatine capsules (EHGCs) and menthol products. NecLife is one of the largest manufacturers of cephalosporin range of products and has an established brand presence in 20 states across India and 50 countries across five continents. NecLife has a global leadership position in 3 oral molecules and global No. 2 position in 2 sterile molecule. The Company has 11 manufacturing facilities – eight in Derabassi, Punjab (API and menthol units), two in Baddi, Himachal Pradesh (FDF and EHGC plants) and one in Jammu (menthol plant). NecLife's products include Oral and sterile cephalosporin, Carbapenem and other APIs, FDFs, Empty hard gelatin capsules and Menthol and allied products.

Additional information on NecLife is available on the Company website www.neclife.com.

Investor contacts

Dinesh Dua

Nectar Lifesciences Limited

Phone: +91 172 304 7766

Fax: +91 172 503 3537

Email: dinesh.dua@neclife.com

Ishan Selarka

Citigate Dewe Rogerson

Phone : +91 22 6645 1232

Fax: +91 22 6645 1213

Email: ishan@cdr-india.com

Note: This document contains 'forward-looking' statements at places. The Company has operations across several segments of business and remains subject to undetermined contingencies and risks. Nectar Lifesciences would not be liable for any action undertaken based on such 'forward-looking' statements and does not commit to revising/updating them publicly.

Certified to be true copy
For Nectar Lifesciences Limited


Sunder Lal
Company Secretary